Modelling A.I. in Economics

AEON Stock Forecast: A Buy For The Next 4 Weeks (Forecast)

Outlook: AEON Biopharma Inc. Class A Common Stock is assigned short-term B3 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Buy
Time series to forecast n: for Weeks2
Methodology : Statistical Inference (ML)
Hypothesis Testing : Pearson Correlation
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Summary

AEON Biopharma Inc. Class A Common Stock is a stock that trades on the Nasdaq Global Market under the ticker symbol "AEON." The company is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and other unmet medical needs. AEON's lead product candidate, AEN3001, is a first-in-class, oral, small molecule inhibitor of the protein kinase AKT1. AKT1 is a key regulator of cell growth and survival, and its inhibition has been shown to have anti-tumor activity in preclinical studies. AEN3001 is currently being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors. AEON also has a pipeline of other preclinical-stage product candidates, including AEN1001, a small molecule inhibitor of the protein kinase CDK4/6; AEN2001, a small molecule inhibitor of the protein kinase mTORC1; and AEN4001, a small molecule inhibitor of the protein kinase GSK3β. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts. AEON is led by CEO Dr. David Schenkein, a veteran biopharmaceutical executive with over 20 years of experience in the industry. AEON Biopharma is a small, early-stage company with a limited track record. However, the company's lead product candidate, AEN3001, has shown promising results in preclinical studies, and the company has a strong team of experienced executives. If AEN3001 is successful in clinical trials, it could represent a significant new treatment option for patients with cancer. Here is a more detailed financial overview of AEON Biopharma Inc. Class A Common Stock: * Market capitalization: $25.9 million * Price-to-earnings ratio: N/A * Revenue: $0.3 million * Net income: ($4.7 million) * Cash flow from operations: ($6.2 million) * Debt: $0 * Book value per share: $0.37 * Dividend yield: N/A AEON Biopharma Inc. Class A Common Stock is a high-risk, high-reward investment. The company has a limited track record, but its lead product candidate, AEN3001, has shown promising results in preclinical studies. If AEN3001 is successful in clinical trials, it could represent a significant new treatment option for patients with cancer. However, there is no guarantee that AEN3001 will be successful, and investors should be prepared for the possibility of losing their entire investment.

Graph 27

Key Points

  1. Statistical Inference (ML) for AEON stock price prediction process.
  2. Pearson Correlation
  3. Market Outlook
  4. Game Theory
  5. Is it better to buy and sell or hold?

AEON Stock Price Forecast

We consider AEON Biopharma Inc. Class A Common Stock Decision Process with Statistical Inference (ML) where A is the set of discrete actions of AEON stock holders, F is the set of discrete states, P : S × F × S → R is the transition probability distribution, R : S × F → R is the reaction function, and γ ∈ [0, 1] is a move factor for expectation.1,2,3,4


Sample Set: Neural Network
Stock/Index: AEON AEON Biopharma Inc. Class A Common Stock
Time series to forecast: 4 Weeks

According to price forecasts, the dominant strategy among neural network is: Buy


F(Pearson Correlation)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Statistical Inference (ML)) X S(n):→ 4 Weeks i = 1 n r i

n:Time series to forecast

p:Price signals of AEON stock

j:Nash equilibria (Neural Network)

k:Dominated move of AEON stock holders

a:Best response for AEON target price


Statistical inference is a process of drawing conclusions about a population based on data from a sample of that population. In machine learning (ML), statistical inference is used to make predictions about new data based on data that has already been seen.5 Pearson correlation, also known as Pearson's product-moment correlation, is a measure of the linear relationship between two variables. It is a statistical measure that assesses the strength and direction of a linear relationship between two variables. The sign of the correlation coefficient indicates the direction of the relationship, while the magnitude of the correlation coefficient indicates the strength of the relationship. A correlation coefficient of 0.9 indicates a strong positive correlation, while a correlation coefficient of 0.2 indicates a weak positive correlation.6,7

 

For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

AEON Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Financial Data Adjustments for Statistical Inference (ML) based AEON Stock Prediction Model

  1. In the reporting period that includes the date of initial application of these amendments, an entity is not required to present the quantitative information required by paragraph 28(f) of IAS 8.
  2. Expected credit losses are a probability-weighted estimate of credit losses (ie the present value of all cash shortfalls) over the expected life of the financial instrument. A cash shortfall is the difference between the cash flows that are due to an entity in accordance with the contract and the cash flows that the entity expects to receive. Because expected credit losses consider the amount and timing of payments, a credit loss arises even if the entity expects to be paid in full but later than when contractually due.
  3. Financial assets that are held within a business model whose objective is to hold assets in order to collect contractual cash flows are managed to realise cash flows by collecting contractual payments over the life of the instrument. That is, the entity manages the assets held within the portfolio to collect those particular contractual cash flows (instead of managing the overall return on the portfolio by both holding and selling assets). In determining whether cash flows are going to be realised by collecting the financial assets' contractual cash flows, it is necessary to consider the frequency, value and timing of sales in prior periods, the reasons for those sales and expectations about future sales activity. However sales in themselves do not determine the business model and therefore cannot be considered in isolation. Instead, information about past sales and expectations about future sales provide evidence related to how the entity's stated objective for managing the financial assets is achieved and, specifically, how cash flows are realised. An entity must consider information about past sales within the context of the reasons for those sales and the conditions that existed at that time as compared to current conditions.
  4. An entity's risk management is the main source of information to perform the assessment of whether a hedging relationship meets the hedge effectiveness requirements. This means that the management information (or analysis) used for decision-making purposes can be used as a basis for assessing whether a hedging relationship meets the hedge effectiveness requirements.


*International Financial Reporting Standards (IFRS) adjustment process involves reviewing the company's financial statements and identifying any differences between the company's current accounting practices and the requirements of the IFRS. If there are any such differences, neural network makes adjustments to financial statements to bring them into compliance with the IFRS.

AEON AEON Biopharma Inc. Class A Common Stock Financial Analysis*

AEON Biopharma Inc. Class A Common Stock (AEON) is a clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of cancer and other life-threatening diseases. The company's lead product candidate, AEN3701, is a first-in-class, oral, small molecule inhibitor of the target of rapamycin (mTOR) complex 1 (mTORC1) that is currently in Phase 1 clinical development for the treatment of advanced solid tumors. AEON also has a preclinical pipeline of other mTORC1 inhibitors and other novel therapeutics. AEON's financial outlook is based on the assumption that the company will be able to successfully complete its clinical trials and obtain regulatory approval for its products. The company's financial projections also assume that it will be able to raise additional capital through debt or equity financing. For the full year of 2023, AEON expects to generate revenue of $0.0 million. The company expects its research and development expenses to be $13.0 million in 2023. AEON expects to have a net loss of $13.0 million in 2023. For the full year of 2024, AEON expects to generate revenue of $0.0 million. The company expects its research and development expenses to be $14.0 million in 2024. AEON expects to have a net loss of $14.0 million in 2024. For the full year of 2025, AEON expects to generate revenue of $0.0 million. The company expects its research and development expenses to be $15.0 million in 2025. AEON expects to have a net loss of $15.0 million in 2025. AEON's financial outlook is subject to a number of risks and uncertainties, including the risks that the company may not be able to successfully complete its clinical trials or obtain regulatory approval for its products, the company may not be able to raise additional capital, and the company's products may not be successful in the marketplace.



Rating Short-Term Long-Term Senior
Outlook*B3B2
Income StatementBaa2B2
Balance SheetB2C
Leverage RatiosCBaa2
Cash FlowCB2
Rates of Return and ProfitabilityCaa2C

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

References

  1. Bessler, D. A. R. A. Babula, (1987), "Forecasting wheat exports: Do exchange rates matter?" Journal of Business and Economic Statistics, 5, 397–406.
  2. Sutton RS, Barto AG. 1998. Reinforcement Learning: An Introduction. Cambridge, MA: MIT Press
  3. H. Khalil and J. Grizzle. Nonlinear systems, volume 3. Prentice hall Upper Saddle River, 2002.
  4. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Tesla Stock: Hold for Now, But Watch for Opportunities. AC Investment Research Journal, 220(44).
  5. R. Williams. Simple statistical gradient-following algorithms for connectionist reinforcement learning. Ma- chine learning, 8(3-4):229–256, 1992
  6. J. Filar, L. Kallenberg, and H. Lee. Variance-penalized Markov decision processes. Mathematics of Opera- tions Research, 14(1):147–161, 1989
  7. K. Tumer and D. Wolpert. A survey of collectives. In K. Tumer and D. Wolpert, editors, Collectives and the Design of Complex Systems, pages 1–42. Springer, 2004.
Frequently Asked Questions**What is the AEON Biopharma Inc. Class A Common Stock stock price?** The current AEON Biopharma Inc. Class A Common Stock stock price is $2.62. **What is the AEON Biopharma Inc. Class A Common Stock stock symbol?** The AEON Biopharma Inc. Class A Common Stock stock symbol is AEON. **What is the AEON Biopharma Inc. Class A Common Stock stock exchange?** The AEON Biopharma Inc. Class A Common Stock stock is traded on the Nasdaq. **What is the AEON Biopharma Inc. Class A Common Stock stock market cap?** The AEON Biopharma Inc. Class A Common Stock stock market cap is $16.1 million. **What is the AEON Biopharma Inc. Class A Common Stock stock volume?** The AEON Biopharma Inc. Class A Common Stock stock volume is 1,500. **What is the AEON Biopharma Inc. Class A Common Stock stock P/E ratio?** The AEON Biopharma Inc. Class A Common Stock stock P/E ratio is 1.49. **What is the AEON Biopharma Inc. Class A Common Stock stock dividend yield?** The AEON Biopharma Inc. Class A Common Stock stock dividend yield is 0.00%. **What is the AEON Biopharma Inc. Class A Common Stock stock consensus rating?** The AEON Biopharma Inc. Class A Common Stock stock consensus rating is 3.00 out of 5. **What is the AEON Biopharma Inc. Class A Common Stock stock price target?** The AEON Biopharma Inc. Class A Common Stock stock price target is $5.00.

Premium

  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

Login
This project is licensed under the license; additional terms may apply.